Literature DB >> 22721676

Assessment of gene expression profiles in peripheral occlusive arterial disease.

Serban Bubenek1, Anca Nastase, Ana Maria Niculescu, Sorin Baila, Vlad Herlea, Vadimir Lazar, Liliana Paslaru, Anca Botezatu, Dana Tomescu, Irinel Popescu, Simona Dima.   

Abstract

BACKGROUND: Molecular events responsible for the onset and progression of peripheral occlusive arterial disease (POAD) are incompletely understood. Gene expression profiling may point out relevant features of the disease.
METHODS: Tissue samples were collected as operatory waste from a total of 36 patients with (n = 18) and without (n = 18) POAD. The tissues were histologically evaluated, and the patients with POAD were classified according to Leriche-Fontaine (LF) classification: 11% with stage IIB, 22% with stage III, and 67% with stage IV. Total RNA was isolated from all samples and hybridized onto Agilent 4×44K Oligo microarray slides. The bioinformatic analysis identified genes differentially expressed between control and pathologic tissues. Ten genes with a fold change ≥ 2 (1 with a fold change ≥ 1.8) were selected for quantitative polymerase chain reaction validation (GPC3, CFD, GDF10, ITLN1, TSPAN8, MMP28, NNMT, SERPINA5, LUM, and FDXR). C-reactive protein (CRP) was assessed with a specific assay, while nicotinamide N-methyltransferase (NNMT) was evaluated in the patient serum by enzyme-linked immunosorbent assay.
RESULTS: A multiple regression analysis showed that the level of CRP in the serum is correlated with the POAD LF stages (r(2) = 0.22, P = 0.046) and that serum NNMT is higher in IV LF POAD patients (P = 0.005). The mRNA gene expression of LUM is correlated with the LF stage (r(2) = 0.45, P = 0.009), and the mRNA level of ITLN1 is correlated with the ankle-brachial index (r(2) = 0.42, P = 0.008).
CONCLUSIONS: Our analysis shows that NNMT, ITLN1, LUM, CFD, and TSPAN8 in combination with other known markers, such as CRP, could be evaluated as a panel of biomarkers of POAD.
Copyright © 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22721676     DOI: 10.1016/j.cjca.2012.03.013

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

Review 1.  The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.

Authors:  A Hultgårdh-Nilsson; J Borén; S Chakravarti
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

Review 2.  A role for proteoglycans in vascular disease.

Authors:  Thomas N Wight
Journal:  Matrix Biol       Date:  2018-02-27       Impact factor: 11.583

3.  Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients.

Authors:  Yan Yang; Qi-Hong Wu; Yan Li; Ping-Jin Gao
Journal:  J Hum Hypertens       Date:  2018-06-05       Impact factor: 3.012

4.  Physiological Study on Association between Nicotinamide N-Methyltransferase Gene Polymorphisms and Hyperlipidemia.

Authors:  Xiao-Juan Zhu; Ya-Jun Lin; Wei Chen; Ya-Hui Wang; Li-Qiang Qiu; Can-Xin Cai; Qun Xiong; Fei Chen; Li-Hui Chen; Qiong Zhou; Jiang-Hua Li
Journal:  Biomed Res Int       Date:  2016-11-23       Impact factor: 3.411

Review 5.  Nicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolution.

Authors:  Richard B Parsons; Paul D Facey
Journal:  Biomolecules       Date:  2021-09-28

Review 6.  Vitamin D: Not Just Bone Metabolism but a Key Player in Cardiovascular Diseases.

Authors:  Marcello Izzo; Albino Carrizzo; Carmine Izzo; Enrico Cappello; Domenico Cecere; Michele Ciccarelli; Patrizia Iannece; Antonio Damato; Carmine Vecchione; Francesco Pompeo
Journal:  Life (Basel)       Date:  2021-05-18

7.  Integrated analysis of mRNA and microRNA expression profiles reveals differential transcriptome signature in ischaemic and dilated cardiomyopathy induced heart failure.

Authors:  Xiuli Shao; Xiaolin Zhang; Lei Yang; Ruijia Zhang; Rongli Zhu; Rui Feng
Journal:  Epigenetics       Date:  2020-10-04       Impact factor: 4.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.